Contribution of a European‐Prevalent Variant near CD83 and an East Asian–Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome‐Wide Association Study Meta‐Analyses

OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, and ulcerative colitis, and has been previously investigated for psoriasis (PsO). This meta‐analysis of genome‐wide association studies (GWAS) was performed to identify genetic factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Bing, Nan, Zhou, Huanyu, Chen, Xing, Hirose, Tomohiro, Kochi, Yuta, Tsuchida, Yumi, Ishigaki, Kazuyoshi, Sumitomo, Shuji, Fujio, Keishi, Zhang, Baohong, Valdez, Hernan, Vincent, Michael S., Martin, David, Clark, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361995/
https://www.ncbi.nlm.nih.gov/pubmed/33455090
http://dx.doi.org/10.1002/art.41655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361995/
https://www.ncbi.nlm.nih.gov/pubmed/33455090
http://dx.doi.org/10.1002/art.41655

Ejemplares similares